| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:8442021 | IVR | 10 mg/kg | - | No significant effects observed | - |
| IVR | 50 mg/kg | - | No significant effects observed | - | |
| IVR | 250 mg/kg | 250 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:8603933 | IVR | 5 mg/L | - | No significant effects observed | - |
| IVR | 5000 mg/L | 5000 mg/L | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5000 mg/L | 5000 mg/L | Changes in spleen morphology | Immunological endocrine-mediated perturbations | |
| IVR | 5000 mg/L | 5000 mg/L | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 5000 mg/L | 5000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Increased cholesterol levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.